Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

October 31, 2005

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC-HIVDNA009-00-VP

Trial Locations (14)

10003

NY Blood Ctr./Union Square CRS, New York

10032

HIV Prevention & Treatment CRS, New York

10455

NY Blood Ctr./Bronx CRS, The Bronx

14642

Univ. of Rochester HVTN CRS, Rochester

21201

Project Brave HIV Vaccine CRS, Baltimore

21205

Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore, Baltimore

35294

Alabama Vaccine CRS, Birmingham

37232

Vanderbilt Vaccine CRS, Nashville

63110

Saint Louis Univ. School of Medicine, HVTU, St Louis

94102

San Francisco Vaccine and Prevention CRS, San Francisco

98104

FHCRC/UW Vaccine CRS, Seattle

02115

Brigham and Women's Hosp. CRS, Boston

02215

Fenway Community Health Clinical Research Site (FCHCRS), Boston

02906

Miriam Hospital's HVTU, Providence

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00071851 - Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults | Biotech Hunter | Biotech Hunter